J E Landegent
Overview
Explore the profile of J E Landegent including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
550
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Veuger M, Honders M, Landegent J, Willemze R, Barge R
Leukemia
. 2000 Sep;
14(9):1678-84.
PMID: 10995016
In vitro studies have demonstrated that deoxycytidine kinase (dCK) plays a crucial role in the mechanism of resistance to cytarabine (AraC). The resistant phenotype in vitro is always a result...
2.
Veuger M, Honders M, Landegent J, Willemze R, Barge R
Blood
. 2000 Aug;
96(4):1517-24.
PMID: 10942400
Deficiency of functional deoxycytidine kinase (dCK) is a common characteristic for in vitro resistance to cytarabine (AraC). To investigate whether dCK is also a target for induction of AraC resistance...
3.
Falkenburg J, Wafelman A, Joosten P, Smit W, van Bergen C, Bongaerts R, et al.
Blood
. 1999 Aug;
94(4):1201-8.
PMID: 10438707
Relapse of chronic myeloid leukemia (CML) in chronic phase after allogeneic stem cell transplantation (SCT) can be successfully treated by donor lymphocyte infusion (DLI). However, relapse of accelerated phase CML,...
4.
Melenhorst J, Landegent J, Willemze R, Fibbe W, Falkenburg J
Lancet
. 1999 Jun;
353(9169):2037-8.
PMID: 10376622
No abstract available.
5.
van de Corput M, Dirks R, van Gijlswijk R, van Binnendijk E, Hattinger C, de Paus R, et al.
J Histochem Cytochem
. 1998 Oct;
46(11):1249-59.
PMID: 9774624
With the ongoing progress in human genome projects, many genes are discovered whose function and/or expression pattern are not known. Most of these genes are expressed in relatively low abundance...
6.
Kluin-Nelemans H, Kester M, van deCorput L, Boor P, Landegent J, van Dongen J, et al.
Blood
. 1998 May;
91(11):4224-31.
PMID: 9596670
Patients with the B-cell malignancy hairy cell leukemia (HCL) exhibit a skewed T-cell repertoire with oligoclonal expression or absence of many members of the T-cell receptor (TCR) BV gene families....
7.
Cluitmans F, Esendam B, Veenhof W, Landegent J, Willemze R, Falkenburg J
Ann Hematol
. 1998 Jan;
75(5-6):201-5.
PMID: 9433376
To analyze the role of hematopoietic growth factors (HGFs) and other cytokines in the regulation of hematopoiesis in vivo, we investigated HGFs and cytokine gene expression in appendices obtained from...
8.
van Soest R, Bolk M, Kluck P, Janssen B, Van Kessel A, Wessels H, et al.
Cancer Genet Cytogenet
. 1997 Dec;
100(1):5-9.
PMID: 9406573
As a first step in characterizing a t(5;16)(q31;p11.2) in a patient with the diagnosis refractory anemia with ring sideroblasts, a cell fusion was carried out between bone marrow cells from...
9.
Melenhorst J, van Krieken J, Dreef E, Landegent J, Willemze R, Fibbe W
Br J Haematol
. 1997 Dec;
99(3):517-9.
PMID: 9401058
Aplastic anaemia (AA) is characterized by pancytopenia and bone marrow (BM) hypocellularity. In some patients AA may be mediated by T cells. To localize inflammatory cell infiltrates, we carried out...
10.
Visser M, Hofstra R, Stulp R, Wu Y, Buys C, Willemze R, et al.
Ann Hematol
. 1997 Nov;
75(3):87-90.
PMID: 9368476
Expression of the tyrosine kinase receptor RET has previously been detected in normal hematopoietic cells, and especially in cells of the myeloid lineage. Furthermore, RET was shown to be differentially...